Life After PTSD, the developers of a leading PTSD treatment protocol, is investigating the use of Brain Scientific’s NeuroCap^TM and NeuroEEG^TM system in its PTSD protocol

LAKEWOOD RANCH, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSFD), a Florida-based applied science technology company, announces today that it is collaborating closely with Life After PTSD (www.lifeafterptsd.org), which has purchased Brain Scientific’s complete solution, NeuroCap and NeuroEEG, to determine how it could be incorporated into Life After PTSD’s groundbreaking Managing Emotional States Effectively© (MESE) protocol to treat PTSD.

“We believe Brain Scientific’s easy-to-use, quick-to-setup, integrated EEG solution will be an important component in our PTSD protocol,” said Edward Maerkl, LMHC, first responder, veteran and one of the co-creators of the MESE protocol. “Our protocol is currently used by 80 practitioners who have used it successfully on more than 1,500 patients. This partnership will help us expand the protocol to thousands of practitioners across the United States.”

Life After PTSD’s MESE protocol is the result of a collaboration between a psychiatrist, counselor and first responder to create a protocol based on the latest developments in brain science and counseling that can be learned quickly and used confidently by mental health professionals and community helpers alike. This revolutionary protocol allows clients to revisit distressing and traumatic memories from a safe distance, guided by a trained clinician or paraprofessional, to allow an alternate experience in which the event is significantly less triggering, with an enhanced ability to move forward.

“It’s important to us to create products that are not only groundbreaking but also making an important and positive difference in our world,” said Hassan Kotob, CEO of Brain Scientific. “We’re delighted that Life After PTSD has selected Brain Scientific’s integrated system to help them expand their PTSD treatment protocol and help those impacted by PTSD live better lives.”

About Brain Scientific

Brain Scientific Inc. (brainscientific.com) is an applied sciences technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of medical and OEM devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of OEM devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.

CONTACTS

LIFE AFTER PTSD
info@lifeafterptsd.org

INVESTORS
ir@brainscientific.com

MEDIA
pr@brainscientific.com

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com